Shots: The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized patients, and is sponsored by the NIAID Lilly trusts the judgment & supports independent DSMB… Read More »Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns
PRISYM ID appoints Software Delivery Manager to oversee team developing new clinical labeling solutions Wokingham, United Kingdom — 30 September 2020 — PRISYM ID, a leading provider of regulated content and label management solutions, has announced the appointment of Amresh Bangalore as Software Delivery Manager. In his new role, Amresh will be responsible for overseeing and coordinating the people, resources and processes… Read More »PRISYM ID appoints Software Delivery Manager to oversee clinical labeling team
The clinical manifestations of COVID-19 are varied, and patients are known to have rapidly changing signs and symptoms that must be tracked with laboratory testing. A patient may start his treatment journey with his primary care physician and will include lab centers, diagnostic centers, inpatient,… Read More »Terminology standards bridging gaps between health systems during COVID-19
CMS requirements for approved clinical decision support mechanisms could cause extra burden and more keystrokes for physicians attempting to meet appropriate use criteria.